[BRATS 13: The use of insulin glargine and insulin detemir to control type 1 diabetes mellitus]
Department of Science and Technology - Brazilian Health Technology Assessment General Coordination (DECIT-CGATS), National Health Surveillance Agency (ANVISA) and National Supplementary Health Agency (ANS)
Record ID 32011000248
Insulin glargine and insulin detemir are long-acting insulin analogues and were released in recent years as alternatives to NPH insulin. This bulletin’s goal is to evaluate whether or not these new insulins are more effective than NPH insulin in relation to glycemic control and regarding the occurrence of hypoglycemic episodes in adults, adolescents and children.
Since the currently available clinical evidence does not uphold the clinical superiority of insulin analogs in relation to NPH, and since the costs associated to the former are greater, the financial resources should be directed towards structuring programs that aim to maximize the benefits of the treatment currently available through the SUS for controlling IDDM.
English language abstract:
An English language summary is available
- Blood Glucose Self-Monitoring
- Diabetes Mellitus, Type 1
- Hypoglycemic Agents
Coordenação-Geral de Fomento à Pesquisa e Avaliação de Tecnologias em Saúde, Departamento de Ciência e Tecnologia
Ministerio da Saude, Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia, Esplanada dos Ministerios, Edificio sede; bl "G" - 8 andar - SL 834, CEP: 70058-900, Brasilia, DF Brazil, Tel: +55 61 3315 3197 Fax: +55 61 3315 3850
Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS)